share_log

Needham Reiterates Buy on Day One Biopharmaceutical, Maintains $33 Price Target

Needham Reiterates Buy on Day One Biopharmaceutical, Maintains $33 Price Target

Needham重申Day One生物制药的买入评级,维持33美元的目标价。
Benzinga ·  06/19 05:37

Needham analyst Ami Fadia reiterates Day One Biopharmaceutical (NASDAQ:DAWN) with a Buy and maintains $33 price target.

Needham分析师Ami Fadia重申Day One Biopharmaceutical(纳斯达克:DAWN)买入评级,并维持33美元的目标价。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发